{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:30:22Z","timestamp":1789173022157,"version":"build-2803163510"},"reference-count":44,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,9,22]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec id=\"s1\">\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To characterise changes in selected haematological parameters following once-daily oral baricitinib dosing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s2\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were pooled from eight randomised clinical trials (four phase 3, three phase 2, one phase 1b) and one long-term extension. Changes in haematological parameters were evaluated up to 128\u00a0weeks (N=2387); overall safety of baricitinib was assessed up to 6\u00a0years (N=3492).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s3\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mean absolute neutrophil counts decreased (\u22121.36\u00d710<jats:sup>9<\/jats:sup>\/L) within 1\u00a0month, followed by stabilisation within the normal reference range through week 128. The incidence of serious infections was not elevated in patients with neutropenia during the 24-week placebo-controlled period. Mean lymphocyte counts increased (+0.30\u00d710<jats:sup>9<\/jats:sup>\/L) within 1\u00a0month, then decreased to baseline (weeks 12\u201324). Mean platelet counts increased at week 2 (+51\u00d710<jats:sup>9<\/jats:sup>\/L), then decreased towards baseline. Overall, mean haemoglobin concentrations decreased (\u22120.12\u00a0mmol\/L), then returned to baseline; however, reduced baseline haemoglobin concentrations observed in the highest baseline high-sensitivity C reactive protein quartile increased over time. Permanent drug discontinuation occurred due to laboratory abnormalities related to neutrophil count in 8 (0.2%), lymphocyte counts in 6 (0.2%), platelet counts in 8 (0.2%), and haemoglobin levels in 16 (0.5%) of all baricitinib-treated patients (N=3492 with 7993 total person-years of exposure).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s4\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Moderate decreases in neutrophils were seen during baricitinib treatment; however, serious infection was uncommon in patients with neutropenia. Transient increases were observed in lymphocytes and platelets, which returned to baseline over time. Changes in haemoglobin concentration were generally small. Haematological abnormalities seldom led to drug discontinuation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001370","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T05:30:13Z","timestamp":1602048613000},"page":"e001370","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":39,"title":["Changes in selected haematological parameters associated with JAK1\/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct01721044","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01721057","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01711359","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8970-4260","authenticated-orcid":false,"given":"Jonathan","family":"Kay","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, UMass Memorial Medical Center, Worcester, Massachusetts, USA"},{"name":"Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA"},{"name":"Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Rancourt","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Dickson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0786-7489","authenticated-orcid":false,"given":"Thomas","family":"Melby","sequence":"additional","affiliation":[{"name":"Syneos Health, Morrisville, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Issa","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0037-6134","authenticated-orcid":false,"given":"Inmaculada","family":"de la Torre","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0820-7167","authenticated-orcid":false,"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabela","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5732-1604","authenticated-orcid":false,"given":"Chadi","family":"Saifan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6606-0071","authenticated-orcid":false,"given":"Edward C","family":"Keystone","sequence":"additional","affiliation":[{"name":"Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-8663","authenticated-orcid":false,"given":"Ronald F","family":"van Vollenhoven","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Amsterdam Universitair Medische Centra, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-0402","authenticated-orcid":false,"given":"Jon T","family":"Giles","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7033-7520","authenticated-orcid":false,"given":"Tom WJ","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leids Universitair Medisch Centrum, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6674-9901","authenticated-orcid":false,"given":"Joel M","family":"Kremer","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Albany Medical College, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"2025090313374458000_6.3.e001370.1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10067-017-3962-5","article-title":"Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice","volume":"37","author":"Versteeg","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025090313374458000_6.3.e001370.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.41.3.242"},{"key":"2025090313374458000_6.3.e001370.3","doi-asserted-by":"publisher","DOI":"10.1177\/014107688908200808"},{"key":"2025090313374458000_6.3.e001370.4","first-page":"1017","article-title":"Rheumatoid arthritis with anaemia and thrombocytopenia","volume":"65","author":"Innes","year":"1972","journal-title":"Proc R Soc Med"},{"key":"2025090313374458000_6.3.e001370.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.3.162"},{"key":"2025090313374458000_6.3.e001370.6","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(90)90001-V"},{"key":"2025090313374458000_6.3.e001370.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105197"},{"key":"2025090313374458000_6.3.e001370.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05189.x"},{"key":"2025090313374458000_6.3.e001370.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh512"},{"key":"2025090313374458000_6.3.e001370.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"2025090313374458000_6.3.e001370.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew329"},{"key":"2025090313374458000_6.3.e001370.12","first-page":"2177","article-title":"Association of anemia and physical disability among patients with rheumatoid arthritis","volume":"34","author":"Han","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090313374458000_6.3.e001370.13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.semarthrit.2017.08.001","article-title":"Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: new evidence from real-world data","volume":"47","author":"Paul","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313374458000_6.3.e001370.14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/0394632017714695","article-title":"Anti-TNF-alpha effects on anemia in rheumatoid and psoriatic arthritis","volume":"30","author":"Corrado","year":"2017","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2025090313374458000_6.3.e001370.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.7"},{"key":"2025090313374458000_6.3.e001370.16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"2025090313374458000_6.3.e001370.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2025090313374458000_6.3.e001370.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"2025090313374458000_6.3.e001370.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"2025090313374458000_6.3.e001370.20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis & Rheumatol"},{"key":"2025090313374458000_6.3.e001370.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206478"},{"key":"2025090313374458000_6.3.e001370.22","unstructured":"INCB028050 compared to background therapy in patients with active rheumatoid arthritis (RA) with inadequate response to disease modifying anti-rheumatic drugs. 04\/09\/2018 ed: Clinicaltrials.gov , 2018."},{"key":"2025090313374458000_6.3.e001370.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150613"},{"key":"2025090313374458000_6.3.e001370.24","unstructured":"Common terminology criteria for adverse events v3.0 (CTCAE): national cancer institute, cancer therapy evaluation program (CTEP)."},{"key":"2025090313374458000_6.3.e001370.25","unstructured":"McInnes IB , Simon LS , Moots RJ , et al. An evaluation of absolute neutrophil count as a biomarker of inflammatory and clinical disease activity in baricitinib-treated patients. ACR\/ARHP 2017 annual meeting . San Diego, CA: Arthritis & Rheumatology, 2017."},{"key":"2025090313374458000_6.3.e001370.26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis & Rheumatol"},{"key":"2025090313374458000_6.3.e001370.27","article-title":"Changes in hemoglobin (Hb) and other hematologic parameters in patients (pts) with rheumatoid arthritis (RA) from baricitinib (Bari) clinical studies","volume":"28","author":"Harigai","year":"2018","journal-title":"Modern Rheumatol"},{"key":"2025090313374458000_6.3.e001370.28","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis & Rheumatol"},{"key":"2025090313374458000_6.3.e001370.29","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/bcp.13612","article-title":"Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: a phase 1, randomized, placebo-controlled, dose-escalation study","volume":"84","author":"Peeva","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2025090313374458000_6.3.e001370.30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025090313374458000_6.3.e001370.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210104"},{"key":"2025090313374458000_6.3.e001370.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"2025090313374458000_6.3.e001370.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.2281"},{"key":"2025090313374458000_6.3.e001370.34","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"2025090313374458000_6.3.e001370.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361"},{"key":"2025090313374458000_6.3.e001370.36","unstructured":"Giles JT , Nurmohamed MT , Rinder HM , et al. Mean platelet volume changes with baricitinib indicate reduced new platelet production in baricitinib-treated rheumatoid arthritis patients. ACR\/ARHP 2018 annual meeting. Arthritis & Rheumatol 2018. Available https:\/\/acrabstracts.org\/abstract\/mean-platelet-volume-changes-with-baricitinib-indicate-reduced-new-platelet-production-in-baricitinib-treated-rheumatoid-arthritis-patients\/"},{"key":"2025090313374458000_6.3.e001370.37","doi-asserted-by":"crossref","first-page":"9213074","DOI":"10.1155\/2019\/9213074","article-title":"Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions","volume":"2019","author":"Korniluk","year":"2019","journal-title":"Mediators Inflamm"},{"key":"2025090313374458000_6.3.e001370.38","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.653391"},{"key":"2025090313374458000_6.3.e001370.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03498.x"},{"key":"2025090313374458000_6.3.e001370.40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bcmd.2013.09.004","article-title":"Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells","volume":"52","author":"McCranor","year":"2014","journal-title":"Blood Cells Mol Dis"},{"key":"2025090313374458000_6.3.e001370.41","doi-asserted-by":"publisher","DOI":"10.1042\/bj2650621"},{"key":"2025090313374458000_6.3.e001370.42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-856500"},{"key":"2025090313374458000_6.3.e001370.43","doi-asserted-by":"crossref","DOI":"10.1186\/ar4397","article-title":"Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis","volume":"15","author":"Isaacs","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2025090313374458000_6.3.e001370.44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01510"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:37:55Z","timestamp":1756931875000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,10,6]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/rmdopen-2020-001370"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001370","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}